Theravance Biopharma, Inc. Debt Securities, Available-for-sale
Theravance Biopharma, Inc. (TBPH) had Debt Securities, Available-for-sale of $222.23 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Assets
us-gaap:AvailableForSaleSecuritiesDebtSecurities · last filed 2026-08-11
- 2026-06-30: Debt Securities, Available-for-sale $222.23M.
- 2026-03-31: Debt Securities, Available-for-sale $131.48M.
- 2025-12-31: Debt Securities, Available-for-sale $240.05M.
- 2025-09-30: Debt Securities, Available-for-sale $203.96M.
| Period end | Debt Securities, Available-for-sale | Debt Securities, Available-for-sale as first filed |
|---|---|---|
| 2026-06-30 | $222.23M 10-Q · filed 2026-08-11 | |
| 2026-03-31 | $131.48M 10-Q · filed 2026-05-07 | |
| 2025-12-31 | $240.05M 10-Q · filed 2026-08-11 | |
| 2025-09-30 | $203.96M 10-Q · filed 2025-11-12 | |
| 2025-06-30 | $332.31M 10-Q · filed 2025-08-13 | |
| 2025-03-31 | $124.46M 10-Q · filed 2025-05-12 | |
| 2024-12-31 | $58.03M 10-K · filed 2026-03-23 | $58.58M 10-K · filed 2025-03-07 |
| 2024-09-30 | $82.64M 10-Q · filed 2024-11-14 | |
| 2024-06-30 | $86.51M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $75.34M 10-Q · filed 2024-05-15 | |
| 2023-12-31 | $89.06M 10-K · filed 2025-03-07 | |
| 2023-09-30 | $120.89M 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $158.18M 10-Q · filed 2023-08-09 | |
| 2023-03-31 | $241.38M 10-Q · filed 2023-05-10 | |
| 2022-12-31 | $303.54M 10-K · filed 2024-03-01 | |
| 2022-09-30 | $474.92M 10-Q · filed 2022-11-09 | |
| 2022-06-30 | $92.26M 10-Q · filed 2022-08-08 | |
| 2022-03-31 | $106.40M 10-Q · filed 2022-05-06 | |
| 2021-12-31 | $133.73M 10-K · filed 2023-03-01 | |
| 2021-09-30 | $185.62M 10-Q · filed 2021-11-08 | |
| 2021-06-30 | $235.50M 10-Q · filed 2021-08-05 | |
| 2021-03-31 | $157.27M 10-Q · filed 2021-05-06 | |
| 2020-12-31 | $211.47M 10-K · filed 2022-02-28 | |
| 2020-09-30 | $307.68M 10-Q · filed 2020-11-09 | |
| 2020-06-30 | $384.24M 10-Q · filed 2020-08-10 | |
| 2020-03-31 | $433.10M 10-Q · filed 2020-05-08 | |
| 2019-12-31 | $274.16M 10-K · filed 2021-02-26 | |
| 2019-09-30 | $334.77M 10-Q · filed 2019-11-08 | |
| 2019-06-30 | $367.31M 10-Q · filed 2019-08-05 | |
| 2019-03-31 | $425.32M 10-Q · filed 2019-05-10 | |
| 2018-12-31 | $501.67M 10-K · filed 2020-02-27 | |
| 2018-09-30 | $308.24M 10-Q · filed 2018-11-08 | |
| 2018-06-30 | $355.05M 10-Q · filed 2018-08-02 | |
| 2018-03-31 | $403.82M 10-Q · filed 2018-05-09 | |
| 2017-12-31 | $370.23M 10-K · filed 2019-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |